Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
43,587,619
-
Share change
-
+466,006
-
Total reported value
-
$520,873,933
-
Price per share
-
$11.95
-
Number of holders
-
81
-
Value change
-
+$5,424,992
-
Number of buys
-
41
-
Number of sells
-
24
Institutional Holders of KINNATE BIOPHARMA INC - COM (KNTE) as of Q3 2022
As of 30 Sep 2022,
KINNATE BIOPHARMA INC - COM (KNTE) was held by
81 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,587,619 shares.
The largest 10 holders included
Foresite Capital Management IV, LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Nextech Invest AG, FMR LLC, BlackRock Inc., Vida Ventures Advisors, LLC, VIKING GLOBAL INVESTORS LP, Lynx1 Capital Management LP, and BOXER CAPITAL, LLC.
This page lists
81
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.